◆英語タイトル:Grunenthal GmbH - Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1779
◆発行会社(調査会社):
GlobalData
◆発行日:2019年11月
◆ページ数:33
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Grunenthal GmbH – Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights
Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company. It researches, develops and markets products for the treatment of pain and innovative formulations of established active substances. The company provides new chemical entities including opioids for moderate to severe pain, vanilloid receptors and KCNQ channel openers for chronic neuropathic pain; and the Bradykinin receptor for the treatment of chronic diseases with inflammation. Grunenthal also focuses on discovering new methods to treat pain, developing new medical devices, and new platform technologies for drug delivery. The company operates along with subsidiaries in Europe, Latin America and the US. Grunenthal is headquartered in Aachen, Germany.
Grunenthal GmbH Key Recent Developments
May 02,2019: Five young scientists win EFIC-Grunenthal grant 2018
Jan 22,2019: Grunenthal appoints Fabian Raschke as Chief Financial Officer (CFO)
Dec 07,2018: Research project aims to make pain “visible”
Oct 31,2018: AstraZeneca signs $922m licensing deal with Grünenthal
Jun 15,2018: Grunenthal Selected as One of the Best Employers in Europe for the Third Time
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Grunenthal GmbH – Key Facts
Grunenthal GmbH – Key Employees
Grunenthal GmbH – Key Employee Biographies
Grunenthal GmbH – Major Products and Services
Grunenthal GmbH – History
Grunenthal GmbH – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Grunenthal GmbH – Business Description
R&D Overview
Grunenthal GmbH – Corporate Strategy
Grunenthal GmbH – SWOT Analysis
SWOT Analysis – Overview
Grunenthal GmbH – Strengths
Grunenthal GmbH – Weaknesses
Grunenthal GmbH – Opportunities
Grunenthal GmbH – Threats
Grunenthal GmbH – Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Grunenthal GmbH, Recent Deals Summary
Section 4 – Company’s Recent Developments
May 02, 2019: Five young scientists win EFIC-Grunenthal grant 2018
Jan 22, 2019: Grunenthal appoints Fabian Raschke as Chief Financial Officer (CFO)
Dec 07, 2018: Research project aims to make pain “visible”
Oct 31, 2018: AstraZeneca signs $922m licensing deal with Grünenthal
Jun 15, 2018: Grunenthal Selected as One of the Best Employers in Europe for the Third Time
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Grunenthal GmbH, Key Facts
Grunenthal GmbH, Key Employees
Grunenthal GmbH, Key Employee Biographies
Grunenthal GmbH, Major Products and Services
Grunenthal GmbH, History
Grunenthal GmbH, Other Locations
Grunenthal GmbH, Subsidiaries
Grunenthal GmbH, Key Competitors
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Grunenthal GmbH, Recent Deals Summary
List of Figures
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019